VETADINE

Main information

  • Trade name:
  • VETADINE PVP IODINE SPRAY
  • Pharmaceutical form:
  • TOPICAL AEROSOL SPRAY
  • Units in package:
  • 450mL
  • Class:
  • Veterinary Medicine
  • Medicine domain:
  • Animals
  • Medicine type:
  • Allopathic drug
  • Manufactured by:
  • BAYER AUSTRALIA

Documents

Localization

  • Available in:
  • VETADINE PVP IODINE SPRAY
    Australia
  • Language:
  • English

Therapeutic information

  • Therapeutic group:
  • CAT | CATTLE | DOG | HORSE | SHEEP | BEEF | BITCH | BOS INDICUS | BOS TAURUS | BOVINE | BUFFALO | BULL | BULLOCK | CALF | CASTRA
  • Therapeutic area:
  • skin treatment
  • Therapeutic indications:
  • ANTIBIOTIC - ANTI-INFECTIVE | CRACKING & CHAPPING OF TEAT | MASTITIS | ABRASIONS | ABSCESSES | AIRSACCULITIS | ANTISEPTIC | AVIAN MYCOPLASMAS | BLACKHEAD | BODY ODOURS | BOWED TENDONS | BROAD SPECTRUM | BURNS | COCCIDIOSIS | COLIFORM COMPLEX | CONJUNCTIVITIS | COWPOX | CRACKS | CRUSTS | DANDRUFF | DERMATOLOGICAL DISORDERS | DERMATOSIS | DRY SKIN | DYSENTERY | ECZEMA | ENDOMETRITIS | ENTERIC DISEASES | ENZOOTIC PNEUMONIA | FEED EFFICIENCY | FUNGAL INFECTIONS | GIRTH GALLS | INFECTIONS | INFLAMMED PADS | ITCHING | KERATOLYTIC | LACERATIONS | MASTITIS | MYCOPLASMAS | ODOURS | OPEN WOUNDS | OTITIS | PRURITIS | QUEENSLAND ITCH | RESPIRATORY DISEASE | SADDLE RASH | SALMONELLOSIS | SCABS | SCALY SKIN | SHEATH ROT | SKIN IRRITATIONS | SORES | SUBCLINICAL MASTITIS | SWINE DYSENTERY | TEAT CRACKING | TEAT INFECTIONS | TOPICAL INFECTIONS | UDDER SORES | UDDER TEAT CRACKING/CHAPPING | WEIGHT GAIN | WIRE CUTS | WOUNDS
  • Product summary:
  • Antibacterial and antifungal skin dressing for horses, cattle, sheep, goats, dogs and cats.Repeated use on open wounds is not recommended

Other information

Status

  • Source:
  • Australian Pesticides and Veterinary Medicines Authority (APVMA)
  • Authorization status:
  • Registered but not available
  • Authorization number:
  • 36013/0202
  • Authorization date:
  • 08-03-2002
  • Last update:
  • 15-06-2017

Patient Information leaflet: composition, indications, side effects, dosage, interactions, adverse reactions, pregnancy, lactation

Version Controlled

Draft

Label

VETADlil/E

IODINE

SPRAY

Last

Edded

30/01120023.-24

Page

Matn panel

POISON

KEEP

OUT OF

REACH

OF CHILDREN

FOR ANIMAL

TREATMENT

ONL Y

VETADINE

IODINE

SPRAY

Active constituent:

Each mL contains 43.5mg POLYVINYLPYRROLIDONE-IODINE

ANTIBACTERIAL AND ANTIFUNGAL SKIN DRESSING

HORSES,

CATTLE,

SHEEP,

GOATS,

DOGS AND CATS

450mL

BOMAC LABORATORIES

Ancillary panel

VETADINE

IODINE

SPRAY

INDICATIONS:

As an aid in the treatment or prevention

local infections in cases of wounds,

abcesses,

burns and fungal

infections eg disinfection

the navel, removal

horns,

castration,

ringworm, disinfection prior

injection

surgery.

Suitable for cut

teat

and udder wounds.

May be sprayed on teats at

drying off time to assist

mastitis control.

Repeated use on open wounds is not

recommended.

Does not stain, burn or blister the skin and is fully scourable.

Does not stain skin or clothing permanently.

DIRECTIONS

USE:

Shake well.

Spray at

a distance

8-15cm from wound.

Usually one treatment

is sufficient to prevent

infection.

If used therapeutically when infection is present,

treatment may be repeated several times daily as

required.

WITHHOLDING

PERIODS NIL.

Government regulations limit iodine residues in milk.

Thoroughly wash residues of Vetadine from the

teats of

udders

prior

to milking.

FIRST

AID:

If poisoning occurs, contact a doctor or Poisons Information Centre.

Phone,

126.

WARNING:

Flammable

N.R.A.

APPROVED

48,EL

rrEXT)

Label

,3(,9!~.).9292,

Date:

-32.,

..

.

Signature:

:::....

t:.f.:

(./.'

......

Version ControlJed Draft

Label

VETADINE

PVP

IODINE

SPRA Y

Last Edited

30/01/2002

3:24

PM

Page

2

of

2

Manufactured by Bomac Laboratories Limited.

Distributed by:

Tech

Pty Limited ACN 084 248 206

8 Apollo Avenue

West

Pymble

2073

Orders

&

Product Information Call

0500886

DISPOSAL:

Dispose

empty container by 'mapping with paper and placing in garbage.

STORAGE:

Store below 30°C (Room temperature).

D2-D /.-

Approval

36013/xxx:,

Expiry Date:

Batch Number:

21-12-2018

National Research Programme for Environmental and Occupational Health:  43 projects selected and €7.4 million mobilised  for the 2018 calls for projects

National Research Programme for Environmental and Occupational Health: 43 projects selected and €7.4 million mobilised for the 2018 calls for projects

Today, ANSES is publishing the list of projects selected as part of its two 2018 calls for research projects for the National Research Programme for Environmental and Occupational Health: the first for projects on a general theme, and the second on the theme of "radiofrequencies and health". Following the selection process, 43 projects were selected with funding amounting to a total of 7.4 million euros.

France - Agence Nationale du Médicament Vétérinaire

31-10-2018

Updated review of the existing maximum residue levels for imazalil according to Article 12 of Regulation (EC) No 396/2005 following new toxicological information

Updated review of the existing maximum residue levels for imazalil according to Article 12 of Regulation (EC) No 396/2005 following new toxicological information

Published on: Tue, 30 Oct 2018 00:00:00 +0100 In compliance with Article 43 of Regulation (EC) No 396/2005, EFSA received a mandate from the European Commission to provide an update of the reasoned opinion on the review of existing maximum residue levels (MRLs) for imazalil published on 5 September 2017, taking into account the additional information provided on the toxicity of the metabolites R014821, FK‐772 and FK‐284. EFSA did not derive MRL proposals from the post‐harvest uses reported on citrus fru...

Europe - EFSA - European Food Safety Authority Publications

7-8-2018

Seaweed consumption: remain vigilant to the risk of excess iodine intake

Seaweed consumption: remain vigilant to the risk of excess iodine intake

Over the last few years, seaweed has become increasingly common on our plates. Fresh, dried or as a food supplement, its iodine content varies and can sometimes be high. ANSES assessed the risk of excess iodine intake from the consumption of seaweed-based products. In view of the non-negligible risk of exceeding the upper limit of safe intake for iodine, the Agency advises against the consumption of seaweed and seaweed-based food supplements by certain at-risk populations, and recommends that regular con...

France - Agence Nationale du Médicament Vétérinaire

20-7-2018

Statement from FDA Commissioner Scott Gottlieb, M.D., on agency’s efforts to encourage the development of and broaden access to generic versions of opioid analgesics that are formulated to deter abuse

Statement from FDA Commissioner Scott Gottlieb, M.D., on agency’s efforts to encourage the development of and broaden access to generic versions of opioid analgesics that are formulated to deter abuse

FDA posted a new batch of 43 product-specific guidances related to the development of generic drug products that includes three revised product-specific guidances for ADF opioid products. These guidances recommend specific in vivo studies and in vitro study considerations for abuse deterrence evaluations.

FDA - U.S. Food and Drug Administration

15-6-2018

Compounded Products Containing Triamcinolone-Moxifloxacin by Guardian Pharmacy Services (Dallas, Texas): Alert to Health Professionals - Adverse Events Reported After Receiving Eye Injections

Compounded Products Containing Triamcinolone-Moxifloxacin by Guardian Pharmacy Services (Dallas, Texas): Alert to Health Professionals - Adverse Events Reported After Receiving Eye Injections

At least 43 patient reported adverse event after receiving eye injections of Guardian’s Pharmacy Services compounded triamcinolone-moxifloxacin product during cataract surgery. The patients reportedly experienced various symptoms, including vision impairment, poor night vision, loss of color perception, and significant reductions in best-corrected visual acuity and visual fields. FDA identified multiple substances in Guardian’s product, including poloxamer 407 and poloxamer 407 degradants. FDA prepared i...

FDA - U.S. Food and Drug Administration

7-11-2018

ACMD meeting statement, Meeting 43, 11 October 2018

ACMD meeting statement, Meeting 43, 11 October 2018

Advisory Committee on Medical Devices meeting statement

Therapeutic Goods Administration - Australia

6-8-2018

Fampyra (Biogen Netherlands B.V.)

Fampyra (Biogen Netherlands B.V.)

Fampyra (Active substance: fampridine) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)5385 of Mon, 06 Aug 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2097/T/43

Europe -DG Health and Food Safety

25-6-2018

Targretin (Eisai Limited)

Targretin (Eisai Limited)

Targretin (Active substance: bexarotene) - Referral - Commission Decision (2018)4021 of Mon, 25 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/H/A-31/1446/C/326/43

Europe -DG Health and Food Safety

6-6-2018

Tybost (Gilead Sciences Ireland UC)

Tybost (Gilead Sciences Ireland UC)

Tybost (Active substance: cobicistat) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)3686 of Wed, 06 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2572/T/43

Europe -DG Health and Food Safety